| ²é¿´: 539 | »Ø¸´: 6 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
seanxiaoÖ÷¹ÜÇø³¤
|
[½»Á÷]
¹ú¼ÊÒ©Õþ×¢²áÌÖÂÛ½»Á÷
|
||
| Ò©Õþ±ÚÀÝÊÇÒ½Ò©ÆóÒµ×ßÏòÊÀ½ç×î´óµÄ±ÚÀÝ.¹úÄÚÅàѵµÄ»ú»áÒ²ÉÙ,×Éѯ¹«Ë¾Ò²²Î²î²»Æë,¾ÑéÓëÌå»á×îÖØÒª,Ï£Íû´ó¼ÒÄܹ»Ôڴ˶ཻÁ÷ÐĵÃ. |
» ²ÂÄãϲ»¶
Ò©Àíѧ¡¢ÁÙ´²Ò©Ñ§·½Ïò µ÷¼Á
ÒѾÓÐ1È˻ظ´
ÇóÖú ±½Á×Áò°·JP
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ59È˻ظ´
100½ð±Ò °¢ÄªÎ÷ÁÖ¿ËÀάËá¼ØÆ¬BPÒ©µäÖÐÌáµ½µÄ¿ËÀάËá¾ÛºÏÎï¾ßÌå½á¹¹Ê½ÊÇɶ£¿
ÒѾÓÐ2È˻ظ´
ҩѧר˶É격
ÒѾÓÐ3È˻ظ´
ÉÅʳ²¹³ä¼ÁºÏ¹æÐÔ½»Á÷
ÒѾÓÐ0È˻ظ´
Ò»Ö¾Ô¸Õã´óҩѧÇóµ÷¼Á
ÒѾÓÐ1È˻ظ´
¸ßθßѹ·´Ó¦ÇóÖú
ÒѾÓÐ4È˻ظ´
ҩѧBÇøÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÖØÇìÒ½¿Æ´óѧ-È˹¤ÖÇÄÜҽѧѧԺ
ÒѾÓÐ0È˻ظ´
ÖØÇìÒ½¿Æ´óѧ-È˹¤ÖÇÄÜҽѧѧԺ
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

elixir
ʵϰ°æÖ÷
![]()
![]()
![]()
![]()
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 49.7
- Ìû×Ó: 86
- ÔÚÏß:
- ³æºÅ: 186392
- ×¢²á: 2006-02-16
- ÐÔ±ð: GG
- רҵ: Ò©¼Áѧ
7Â¥2006-06-06 16:08:35
seanxiao
¶Ò»»¹ó±ö
![]()
![]()
![]()
![]()
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1393
- Ìû×Ó: 178
- ÔÚÏß: 14.5Сʱ
- ³æºÅ: 155320
- ×¢²á: 2006-01-04
- ÐÔ±ð: GG
- רҵ: Ò©Îïѧ
FDA½âÒÉר¼ÒÁªÏµ·½Ê½
shich68(½ð±Ò+0):ÄãQQ¶àÉÙ?
|
Active Pharmaceutical Ingredients (API) Anthony Charity (301) 827-9005 Anthony.Charity@fda.hhs.gov Albinus D'Sa (301) 827-9044 Albinus.DSa@fda.hhs.gov Monica Caphart (301) 827-9047 Monica.Caphart@fda.hhs.gov Edwin Rivera Martinez (301) 827-9014 Edwin.RiveraMartinez@fda.hhs.gov |

2Â¥2006-05-17 13:53:40
seanxiao
¹ÜÀíÔ±
![]()
![]()
![]()
![]()
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1393
- Ìû×Ó: 178
- ÔÚÏß: 14.5Сʱ
- ³æºÅ: 155320
- ×¢²á: 2006-01-04
- ÐÔ±ð: GG
- רҵ: Ò©Îïѧ
FDA½âÒÉר¼ÒÁªÏµ·½Ê½
|
Cleaning Validation Brian Hasselbalch (301) 827-9046 Brian.Hasselbalch@fda.hhs.gov Albinus D'Sa (301) 827-9044 Albinus.DSa@fda.hhs.gov Mike Gavini (301) 827-9053 Mural.Gavini@fda.hhs.gov |

3Â¥2006-05-17 13:56:28
seanxiao
³¬¼¶°æÖ÷
![]()
![]()
![]()
![]()
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1393
- Ìû×Ó: 178
- ÔÚÏß: 14.5Сʱ
- ³æºÅ: 155320
- ×¢²á: 2006-01-04
- ÐÔ±ð: GG
- רҵ: Ò©Îïѧ

4Â¥2006-05-31 20:57:39














»Ø¸´´ËÂ¥